Predicting Immunotherapy Success Before Surgery for Lung Cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial uses special tests (like looking at genes and proteins) to better understand which patients with non-small cell lung cancer (NSCLC) will benefit most from immunotherapy given before surgery. It aims to create a tool to predict treatment success.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have non-small cell lung cancer (NSCLC) that is stage II or III.
- Your tumor does not have an EGFR or ALK gene mutation.
- You are 18 years or older.
- You are scheduled to receive immunotherapy (a treatment that helps your immune system fight cancer) before surgery.
- You are in good general health (able to do daily activities without help) and expected to live at least 12 weeks.
- You have not had chemotherapy, radiation, or other anti-cancer treatments before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well immunotherapy given before surgery works for non-small cell lung cancer. It aims to help doctors understand real-world outcomes for patients who receive this treatment.
This study compares three different schedules for giving immunotherapy (a cancer-fighting drug) to patients with early-stage non-small cell lung cancer who are having surgery. The goal is to find out which timing—before surgery, after surgery, or both—works best to prevent cancer from coming back.
This trial tests using immunotherapy before surgery or radiation for non-small cell lung cancer. It looks at how safe and effective this approach is and how it affects survival.
This trial is testing a treatment given before surgery for non-small cell lung cancer. Patients receive chemotherapy plus immunotherapy (chemo-immunotherapy) first, then have surgery to remove the tumor. The goal is to see how well this approach works.
This trial studies a comprehensive treatment approach for lung cancer that combines immunotherapy given before surgery with standard surgery. It aims to understand how well this approach works by analyzing your medical data and samples.
This trial looks at giving immunotherapy before surgery for certain early-stage lung cancers to help shrink the tumor and improve outcomes. It is mainly for people whose lung cancer can be removed by surgery and who don’t have specific gene changes like EGFR or ALK.
Hear when a new NSCLC Stage II trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.